Synergy Pharmaceuticals (SGYP) Stock: Gaining On Clinical Data


Synergy Pharmaceuticals Inc (NASDAQ: SGYP) is having a strong morning in the pre-market hours this morning after announcing that it will be presenting data regarding Trulance (plecanatide) at Digestive Disease Week in Chicago. Of course, this led to excitement among investors, pushing the stock upward. Our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:12), SGYP is trading at $4.12 per share after a gain of $0.12 per share (3.00%) thus far today.

SGYP To Present Data At Digestive Disease Week

As mentioned above, Synergy Pharmaceuticals is having a strong start to the trading session this morning after announcing that it would be presenting new data. The data comes from patients with moderate to very severe bloating who participated in the Phase 3 clinical trials surrounding Trulance. In a statement, Satish S.C. Rao, M.D., Ph.D., Professor of Medicine, Division Chief Fellowship Program Director and Director of the Digestive Health Center at Augusta University, had the following to say about the SGYP data:

People living with chronic idiopathic constipation often experience a range of symptoms that can make it more difficult to manage this disorder, including moderate to very severe bloating… The data presented today is consistent with the efficacy and safety results seen from previously published results for Trulance in CIC.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SGYP. In particular, we’re interested in learning more about the data that will soon be released, as Trulance is a promising treatment in the arena of gastrointestinal disease and is already on the market for IBS-C. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Previous articleTribune (TRCO) Stock: Gaining On Acquisition News
Next articleImperva (IMPV) Stock: Spikes On Takeover Rumors
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.


Please enter your comment!
Please enter your name here